GSKGlaxoSmithKlineSigning up patients
A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)
Neoplasms, Endometrial
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 600 (planned)
- Started
- Jun 4, 2026
- Main results expected
- Feb 29, 2028
- Fully finished
- May 30, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Objective response rate (ORR) by BICR
Measured over: Up to approximately 97 weeks
Progression Free Survival (PFS) by BICR
Measured over: Up to approximately 97 weeks
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07286331 · record last updated 2026-11-03 · checked 2026-11-09 15:42 UTC